In the second week of September, Medicilon signed a collaboration agreement with a pharmaceutical company from Zhejiang. Medicilon will provide the preclinical development services on small molecule anti-cancer drugs to the pharmaceutical company and the collaboration will take about 2 years of time. The reason why the pharmaceutical company picked Medicilon is because Medicilon could provide a one stop pharmaceutical service across biology, chemistry and preclinical IND filing.